Strategies for improving the management of immune-related adverse events

With the advent of immunotherapeutic agents, durable and dramatic responses have been observed in several hard-to-treat malignancies, outlining a roadmap to conquering cancer. Immune checkpoint inhibitors (ICPi) are a class of immunotherapeutic agents that attack the tumor cells by reinvigorating th...

Descripción completa

Detalles Bibliográficos
Autores principales: Naing, Aung, Hajjar, Joud, Gulley, James L, Atkins, Michael B, Ciliberto, Gennaro, Meric-Bernstam, Funda, Hwu, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735083/
https://www.ncbi.nlm.nih.gov/pubmed/33310772
http://dx.doi.org/10.1136/jitc-2020-001754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735083/
https://www.ncbi.nlm.nih.gov/pubmed/33310772
http://dx.doi.org/10.1136/jitc-2020-001754

Ejemplares similares